Scarica l'app Stockscreener
0.00
100.00%
-0.78
Dopo l'orario di chiusura:
.70
0.70
+
Eagle Pharmaceuticals Inc Borsa (EGRX) Ultime notizie
Halper Sadeh LLC Encourages Eagle Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights - The AI Journal
Reviewing Eagle Pharmaceuticals (NASDAQ:EGRX) and Bio-Path (NASDAQ:BPTH) - Defense World
Eagle Pharmaceuticals (NASDAQ:EGRX) Share Price Crosses Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
ACA Pharma Announces Major Expansion of RYANODEX® Territory Outside the United States - NEWS CHANNEL NEBRASKA- Northeast
Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Price Passes Below 200 Day Moving Average – What’s Next? - Defense World
Eagle Health Investments LP Cuts Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Indian Society of Anaesthesiologists Hosts Nationwide Launch of Ryanodex® in India - PRWeb
U.S. Vasopressin Market Poised for Transformation with - openPR.com
Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan - The Manila Times
Eagle Pharma (OTCMKTS: EGRX) extends stockholder rights plan to 2026; $20 exercise - Stock Titan
Giant Eagle opens new pharmacy in Mt. Washington, filling gap left by Rite Aid - WTAE
Total debt per share of EAGLE PHARMACEUTICALS INC – OTC:EGRX - TradingView
Revenue per share of Eagle Pharmaceuticals, Inc. – LS:A1XEDS - TradingView
Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders - The Manila Times
Eagle Pharmaceuticals (OTCMKTS: EGRX) posts 82% quorum; directors elected, BDO ratified - Stock Titan
Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements - The Manila Times
Unaudited Q2 2025 financials available — Eagle Pharmaceuticals posts three- and six-month statements - Stock Titan
Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements - The Manila Times
Q1 2025 Unaudited Financials — Eagle Pharmaceuticals posts statements and investor materials available now - Stock Titan
McCarter & English Launches Wave of Pharma Patent Infringement Suits in Delaware - Law.com
EGRX STOCKHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Eagle Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years - The Manila Times
Annual Meeting Alert: Eagle Pharmaceuticals Releases Two Years of Audited Financials Ahead of October Meeting - Stock Titan
Heparin-Induced Thrombocytopenia (HIT) Treatment Market - openPR.com
Can Regeneron Pharmaceuticals Inc. expand its profit marginsJuly 2025 Rallies & Reliable Entry Point Trade Alerts - خودرو بانک
Why American Eagle Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket - inkl
New Report: Bacteriostatic Water for Injection Market Set - openPR.com
Fortune 100 Company Coming to Harrison - Eagle Country 99.3
Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Directors - citybiz
Evaluating the Strategic Impact of Abhinav Jain’s Board Appointment on Eagle Pharmaceuticals and Related Biopharma Players - AInvest
Major 38% Stakeholder Gains Board Seat: Eagle Pharmaceuticals Appoints Nantahala Analyst as Director - Stock Titan
Diffuse Large B-cell Lymphoma Market to Grow at a CAGR of 13% by 2034 in Leading Markets (US, EU4, UK, and Japan) | DelveInsight - The Malaysian Reserve
Bacterial Pneumonia Market Landscape 2032 Therapies, Market Size, Pipeline, Revenue, Future Opportunities, Companies By Delveinsight - MenaFN
Bacterial Pneumonia Market Outlook 2034Clinical Trials, - openPR.com
Eagle Pharmaceuticals Announces 2025 Annual Meeting Date - The Manila Times
Heparin-Induced Thrombocytopenia Market Rises with Novel - openPR.com
Bacterial Pneumonia Market Rises on Tech Diagnostics & Japan's - openPR.com
'Trying to save everybody money': Giant Eagle and Mark Cuban's Cost Plus Drugs are teaming up - WTAE
YMAB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Y-mAbs Therapeutics, Inc. Is Fair to Shareholders - Business Wire
Radius Pharmaceuticals Announces Victory in Patent Infringement Case Against Orbicular Pharmaceutical Technologies for Osteoporosis Treatment TYMLOS(R) - Eagle-Tribune
U.S. Vasopressin Market Growth and Future Scope 2025-2032 | Par - openPR.com
What makes Eagle Financial Services Inc. stock price move sharplyROI Prediction from Long-Term Holding Plans - Newser
SHAREHOLDER ALERT: Levi & Korsinsky Reminds Eagle Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 9, 2024EGRX - ACCESS Newswire
Post-Operative Nausea and Vomiting Market Report 2025: - GlobeNewswire
Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathway - Lancaster Eagle-Gazette
EpiPen Veteran to Lead Aquestive's Revolutionary Oral Epinephrine Launch as New Chief Commercial Officer - Stock Titan
Agnico Eagle Mines Limited (NYSE:AEM) Position Boosted by Principal Financial Group Inc. - Defense World
JTC Team Announces Participating Line Up for the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference - Lancaster Eagle-Gazette
Processa Pharmaceuticals and BullFrog AI Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Eagle-Tribune
Eagle Pharmacy Celebrates 20 Years! - The Millen News
ACA Pharma secures fast-track approval for Eagle Pharmaceuticals' RYANODEX® in Macau - PRWeb
New Strong Buy Stocks for June 25th - TradingView
Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeriaan Ultra-Rare Genetic Disorder that Causes Rapid Aging - Eagle-Tribune
0.20%
1.46%
Capitalizzazione:
|
Volume (24 ore):